Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 17/20 | 0.50 |
| ▸ | HTR2A | P28223 | 16/20 | 0.50 |
| ▸ | DRD3 | P35462 | 16/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7821912 | 0.85 | KCNA3 (0.46) | KCNA3DRD2HTR2ADRD3CCR5 | |
| SCHEMBL6215166 | 0.84 | MAOB (0.53) | DRD2HTR2ADRD3 | |
| SCHEMBL7827907 | 0.84 | KCNA3 (0.46) | KCNA3DRD2HTR2ADRD3CCR5 | |
| SCHEMBL7827014 | 0.82 | USP14 (0.54) | KCNA3DRD2HTR2ADRD3CCR5 | |
| SCHEMBL7824714 | 0.81 | KCNA3 (0.48) | KCNA3DRD2HTR2ADRD3CCR5 | |
| SCHEMBL13584122 | 0.80 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL13584120 | 0.80 | DRD2 (0.78) | DRD2HTR2ADRD3 | |
| SCHEMBL22928915 | 0.80 | KCNA3 (0.66) | KCNA3DRD2HTR2ADRD3CCR5 | |
| SCHEMBL6214213 | 0.79 | DRD2 (0.50) | DRD2HTR2ADRD3 | |
| SCHEMBL5568960 | 0.77 | NPC1 (0.55) | DRD2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266896-B1 | Linear or cyclic ureas, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-17 | — | — | EP | disclosed |
| US-6908922-B2 | Anticholesterol agents; cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-06-21 | — | — | US | disclosed |
| US-6903103-B2 | Linear cyclic ureas | LES LABORATORIES SERVIER (FR) | 2005-06-07 | — | — | US | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030229100-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-11 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| EP-1266896-A1 | Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-6323217-B2 | CARDIOVASCULAR DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | LES LABORATOIRES SERVIER (FR) | 2001-10-25 | — | — | US | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | KCNA3 847/4885DRD2 3536/4885HTR2A 2477/4885 |
| US-20010034352-A1 | Piperidine-4 sulphonamide compounds | KDR, GLS, FLT1 | KCNA3 375/4885DRD2 125/4885HTR2A 59/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | KCNA3 1082/4885DRD2 3284/4885HTR2A 2171/4885 |
| US-20030229100-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | KCNA3 1082/4885DRD2 3284/4885HTR2A 2171/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | KCNA3 1082/4885DRD2 3284/4885HTR2A 2171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.